NAS10029,644+0.67%S&P7,651+0.17%GOLD$4,412−0.30%BTC$81,228−0.01%VIX14.81−4.08%live tape · as of 05:00 UTC
The Screen · Healthcare · Drug Manufacturers - Specialty & Generic
Elanco Animal Health Inc
ELAN · the NYSE · USD · Market cap $11.4B · 9,400 employees
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide.
Positioning political selling, disclosed 2026-08-04
Options no verdict drawn today, left as found
Ethical passes the values gate
Price22.74 USD
Fair value25.49
Ethical score70.0/100
Our investment reviews on this name
2026-08-27Read Distribution22.51+1.0% to today
2026-07-02Read Markup24.17-5.9% to today
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Elanco Animal Health Inc holds its Markdown at $22.74. Consolidating, no directional conviction, held for 44 days.
As held on the ledger · 2026-09-17
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 44 days
Price at the screen
$22.74
Valuation
N/A trailing · 17.68 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.68
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
30.07%
Below 33%
Interest-bearing debt is just 30.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
10.62%
Below 49%
Money owed to the company is 10.6% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-17 screen. The gold marker is the market price at the same screen. A 12.1% margin of safety to the base estimate.
Third-party analyst targets: 14 covering, consensus Strong Buy. The average target sits +39% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-17 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Farm Animals and Pets Drive Steady Revenue
Every time a dairy herd gets vaccinated or a spaniel is treated for fleas, the bill lands with companies like Elanco. Revenue is rising 15 percent, yet the firm still posts a 5 percent loss and negative 4 percent return on equity. A narrow moat and 21.6 times forward earnings leave almost no margin of safety at the current price.
The business clears our ethical screen and analysts see upside to 30 dollars, but our fair value sits only a percent above the market price. That slim gap, combined with ongoing losses, produces an opportunity rating of none.
Animal health can swing with farm incomes and pet spending cycles. One bad season or a competitor launch could widen the losses further. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ELAN trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 12.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 60%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (14 analysts) rates it strong buy, with a mean price target of $30.
2026-07-27Markup$25.83+6.9%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 6.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 60%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (14 analysts) rates it strong buy, with a mean price target of $30.
2026-07-18Markup$24.17+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 60%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (14 analysts) rates it strong buy, with a mean price target of $30.
2026-07-03Markup$24.17+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markup$24.17Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
